• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prevalence of Leukopenia and Associated Outcomes in Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

作者信息

Wang Leo L, Noe Megan H, Micheletti Robert G

机构信息

Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia.

Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.

出版信息

JAMA Dermatol. 2022 Oct 1;158(10):1212-1214. doi: 10.1001/jamadermatol.2022.3011.

DOI:10.1001/jamadermatol.2022.3011
PMID:35976636
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9386600/
Abstract
摘要

相似文献

1
Prevalence of Leukopenia and Associated Outcomes in Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症患者白细胞减少症的患病率及相关结局
JAMA Dermatol. 2022 Oct 1;158(10):1212-1214. doi: 10.1001/jamadermatol.2022.3011.
2
Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis.史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症患儿的发病率、治疗结果及资源利用情况。
Pediatr Dermatol. 2018 Mar;35(2):182-187. doi: 10.1111/pde.13383. Epub 2018 Jan 9.
3
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症与门诊护理中除抗癫痫药和抗生素以外的常用药物有关：一项基于人群的病例对照研究。
Drug Saf. 2019 Jan;42(1):55-66. doi: 10.1007/s40264-018-0711-x.
4
Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum.多形红斑/史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症疾病谱的急性眼部表现分析
Ophthalmology. 1995 Nov;102(11):1669-76. doi: 10.1016/s0161-6420(95)30811-1.
5
Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.药物作为儿童史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的危险因素：一项汇总分析。
Pediatrics. 2009 Feb;123(2):e297-304. doi: 10.1542/peds.2008-1923. Epub 2009 Jan 19.
6
Stevens-Johnson syndrome and toxic epidermal necrolysis at the University Hospital of the West Indies, Jamaica.牙买加西印度大学医院的史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症
West Indian Med J. 2013 Sep;62(7):589-92. doi: 10.7727/wimj.2013.031.
7
Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.重症多形红斑、史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的临床模式与病因之间的相关性：一项国际前瞻性研究的结果
Arch Dermatol. 2002 Aug;138(8):1019-24. doi: 10.1001/archderm.138.8.1019.
8
Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: Data mining the public version of the FDA adverse event reporting system.评估卡马西平和奥卡西平相关的史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症：从 FDA 不良事件报告系统公开版本中挖掘数据。
Int J Clin Pract. 2021 Aug;75(8):e14273. doi: 10.1111/ijcp.14273. Epub 2021 May 17.
9
Haematological disturbances and immune mechanisms in toxic epidermal necrolysis.中毒性表皮坏死松解症中的血液学紊乱与免疫机制
Br J Dermatol. 1986 Feb;114(2):255-9. doi: 10.1111/j.1365-2133.1986.tb02806.x.
10
Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症：文献综述
Ann Allergy Asthma Immunol. 2005 Apr;94(4):419-36; quiz 436-8, 456. doi: 10.1016/S1081-1206(10)61112-X.

引用本文的文献

1
Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease.麻疹样皮疹：鉴别低风险药物疹、严重皮肤不良反应、病毒疹及急性移植物抗宿主病。
Am J Clin Dermatol. 2025 May;26(3):379-393. doi: 10.1007/s40257-025-00924-0. Epub 2025 Jan 31.
2
Treatment of Tislelizumab-Induced Toxic Epidermal Necrolysis and Agranulocytosis: A Case Report and Literature Review.替雷利珠单抗诱导的中毒性表皮坏死松解症和粒细胞缺乏症的治疗：一例报告及文献综述
Curr Drug Saf. 2025;20(3):361-365. doi: 10.2174/0115748863297885240604111018.